PT3326622T - Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática - Google Patents
Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastáticaInfo
- Publication number
- PT3326622T PT3326622T PT171966625T PT17196662T PT3326622T PT 3326622 T PT3326622 T PT 3326622T PT 171966625 T PT171966625 T PT 171966625T PT 17196662 T PT17196662 T PT 17196662T PT 3326622 T PT3326622 T PT 3326622T
- Authority
- PT
- Portugal
- Prior art keywords
- axl
- inhibition
- modified
- peptides
- signaling
- Prior art date
Links
- 230000002001 anti-metastasis Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737276P | 2012-12-14 | 2012-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3326622T true PT3326622T (pt) | 2021-04-07 |
Family
ID=50934967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT171966625T PT3326622T (pt) | 2012-12-14 | 2013-12-12 | Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática |
| PT138627807T PT2931265T (pt) | 2012-12-14 | 2013-12-12 | Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT138627807T PT2931265T (pt) | 2012-12-14 | 2013-12-12 | Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9822347B2 (enExample) |
| EP (2) | EP3326622B1 (enExample) |
| JP (2) | JP6345690B2 (enExample) |
| AU (3) | AU2013359179B2 (enExample) |
| CA (1) | CA2894539C (enExample) |
| DK (2) | DK3326622T3 (enExample) |
| ES (2) | ES2862335T3 (enExample) |
| FI (1) | FI2931265T6 (enExample) |
| NO (1) | NO3049208T3 (enExample) |
| PT (2) | PT3326622T (enExample) |
| WO (1) | WO2014093690A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| RU2556822C2 (ru) * | 2010-01-22 | 2015-07-20 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Ингибирование axl сигнализации в антиметастатической терапии |
| WO2013090776A1 (en) | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl/gas6 signaling in the treatment of disease |
| FI2931265T6 (fi) | 2012-12-14 | 2023-05-23 | Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa | |
| CA2909669C (en) | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| EP3233902B1 (en) * | 2014-12-18 | 2020-09-09 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
| KR20200085307A (ko) * | 2017-11-04 | 2020-07-14 | 아라바이브 바이올로직스, 인크. | Axl 유인 수용체를 이용한 전이성 암의 치료 방법 |
| JP2024533362A (ja) * | 2021-09-11 | 2024-09-12 | アラヴィヴ インコーポレイテッド | Ａｘｌデコイ受容体を一次治療として使用する局所進行又は転移性膵臓腺がんを治療する方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5538861A (en) | 1994-07-29 | 1996-07-23 | Amgen Inc. | DNA encoding a stimulating factor for the axl receptor |
| US20030166107A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| AU2003304180A1 (en) | 2002-09-24 | 2005-01-04 | Dow, Kenneth, Centocor, Inc. | Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses |
| US20070142273A1 (en) | 2003-04-18 | 2007-06-21 | Sherif Daouti | Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis |
| JP2005278631A (ja) | 2004-03-04 | 2005-10-13 | National Institute Of Advanced Industrial & Technology | Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法 |
| CA2630475A1 (en) | 2004-11-24 | 2006-06-01 | The Regents Of The University Of Colorado | Mer diagnostic and therapeutic agents |
| US7932032B2 (en) | 2005-05-02 | 2011-04-26 | Toray Industries, Inc. | Method for diagnosing esophageal cancer |
| US8168415B2 (en) * | 2007-02-07 | 2012-05-01 | The Regents Of The University Of Colorado | Axl fusion proteins as Axl tyrosine kinase inhibitors |
| CN101679313A (zh) | 2007-04-13 | 2010-03-24 | 休普基因公司 | 用于治疗癌症或过度增殖性疾病的axl激酶抑制剂 |
| CA2692320A1 (en) | 2007-07-02 | 2009-01-08 | Wyeth | Methods of treating bone disorders with modulators of axl |
| US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| CA2747678A1 (en) * | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| KR20120035145A (ko) | 2009-05-11 | 2012-04-13 | 우드라이 파마 게엠베하 | 인간화 ａｘｌ 항체 |
| US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| RU2556822C2 (ru) * | 2010-01-22 | 2015-07-20 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Ингибирование axl сигнализации в антиметастатической терапии |
| AU2011326164B2 (en) | 2010-11-08 | 2016-05-05 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| WO2013090776A1 (en) * | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl/gas6 signaling in the treatment of disease |
| US20150315552A1 (en) | 2012-12-14 | 2015-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL Signaling in Primary Tumor Therapy |
| FI2931265T6 (fi) | 2012-12-14 | 2023-05-23 | Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa | |
| US20160266136A1 (en) * | 2013-08-30 | 2016-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | High-affinity binding to gas6 |
| CA2909669C (en) * | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| EP3233902B1 (en) * | 2014-12-18 | 2020-09-09 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
-
2013
- 2013-12-12 FI FIEP13862780.7T patent/FI2931265T6/fi active
- 2013-12-12 US US14/650,854 patent/US9822347B2/en active Active
- 2013-12-12 AU AU2013359179A patent/AU2013359179B2/en not_active Ceased
- 2013-12-12 WO PCT/US2013/074786 patent/WO2014093690A1/en not_active Ceased
- 2013-12-12 EP EP17196662.5A patent/EP3326622B1/en active Active
- 2013-12-12 JP JP2015547567A patent/JP6345690B2/ja active Active
- 2013-12-12 ES ES17196662T patent/ES2862335T3/es active Active
- 2013-12-12 DK DK17196662.5T patent/DK3326622T3/da active
- 2013-12-12 EP EP13862780.7A patent/EP2931265B3/en active Active
- 2013-12-12 PT PT171966625T patent/PT3326622T/pt unknown
- 2013-12-12 PT PT138627807T patent/PT2931265T/pt unknown
- 2013-12-12 CA CA2894539A patent/CA2894539C/en active Active
- 2013-12-12 DK DK13862780.7T patent/DK2931265T6/da active
- 2013-12-12 ES ES13862780T patent/ES2665323T7/es active Active
-
2014
- 2014-06-30 NO NO14741534A patent/NO3049208T3/no unknown
-
2017
- 2017-10-13 US US15/783,850 patent/US11136563B2/en not_active Expired - Fee Related
- 2017-12-06 AU AU2017272193A patent/AU2017272193A1/en not_active Abandoned
-
2018
- 2018-05-23 JP JP2018098435A patent/JP6832887B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-02 AU AU2019210662A patent/AU2019210662B2/en not_active Ceased
-
2021
- 2021-09-02 US US17/465,203 patent/US20220220458A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2931265T3 (en) | 2018-04-16 |
| FI2931265T6 (fi) | 2023-05-23 |
| ES2665323T7 (es) | 2023-06-15 |
| EP3326622B1 (en) | 2021-01-20 |
| AU2013359179B2 (en) | 2017-10-05 |
| ES2862335T3 (es) | 2021-10-07 |
| AU2017272193A1 (en) | 2017-12-21 |
| AU2013359179A1 (en) | 2015-07-02 |
| WO2014093690A1 (en) | 2014-06-19 |
| US9822347B2 (en) | 2017-11-21 |
| DK2931265T6 (da) | 2023-05-01 |
| NO3049208T3 (enExample) | 2018-04-14 |
| CA2894539C (en) | 2021-09-28 |
| JP6832887B2 (ja) | 2021-02-24 |
| ES2665323T3 (es) | 2018-04-25 |
| CA2894539A1 (en) | 2014-06-19 |
| US20150315553A1 (en) | 2015-11-05 |
| US20180030422A1 (en) | 2018-02-01 |
| AU2019210662A1 (en) | 2019-08-22 |
| US11136563B2 (en) | 2021-10-05 |
| EP2931265A1 (en) | 2015-10-21 |
| HK1256071A1 (en) | 2019-09-13 |
| EP2931265A4 (en) | 2016-08-31 |
| JP2016510309A (ja) | 2016-04-07 |
| PT2931265T (pt) | 2018-04-16 |
| EP2931265B1 (en) | 2018-01-31 |
| US20220220458A1 (en) | 2022-07-14 |
| EP2931265B3 (en) | 2023-04-05 |
| EP3326622A1 (en) | 2018-05-30 |
| JP6345690B2 (ja) | 2018-06-20 |
| AU2019210662B2 (en) | 2021-07-01 |
| DK3326622T3 (da) | 2021-04-06 |
| JP2018154641A (ja) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201307676B (en) | Inhibition of axl signaling in anti-metastatic therapy | |
| EP2831001A4 (en) | COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE | |
| GB201218862D0 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| ZA201307797B (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| SG10201707020TA (en) | Substituted 3-haloallylamine inhibitors of ssao and uses thereof | |
| ZA201405858B (en) | Recombinant microorganisms and methods of use thereof | |
| PT2931265T (pt) | Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática | |
| GB201218850D0 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| SG10201609940RA (en) | Compounds and their methods of use | |
| GB201218864D0 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| IL237125A0 (en) | Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors | |
| EP2806811A4 (en) | VERTEBRAL CONSTRUCTION | |
| IL233481A0 (en) | Peptides and methods of using them | |
| EP2872208A4 (en) | SLEEPING SUPPORTING ARTICLE AND METHOD OF APPLICATION THEREFOR | |
| PL2922557T3 (pl) | Suplementy ziołowe i sposoby ich zastosowania | |
| IL234841A0 (en) | Administration forms of halofuginone and methods of use | |
| PL2667880T3 (pl) | Oligopeptydy metaloproteinaz i ich zastosowanie terapeutyczne | |
| PL2790666T3 (pl) | Ekstrakty z maesa japonica i sposoby zastosowania | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| ZA201306861B (en) | Outlet fitting basic body and outlet body therefor | |
| GB201219678D0 (en) | Ketone body inhibitors and uses thereof | |
| EP2836227A4 (en) | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF | |
| ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
| PL2744497T3 (pl) | Terapeutyczne połączenia netupitantu i palonosetronu | |
| EP2877486A4 (en) | PEPTIDE-BASED COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BETA-AMYLOID ACCUMULATION |